| Bioactivity | D3S-001 is an orally active inhibitor for KRAS. D3S-001 inhibits the proliferation of KRASG12C mutant H358 and MIA-PA-CA-2 with an IC50 of 0.6 and 0.44 nM. D3S-001 exhibits good metabolic stability in hepatocytes, liver microsomes, plasma and whole blood in various species. D3S-001 exhibits good pharmacokinetic characteristics and antitumor efficacy in mice[1]. |
| CAS | 2914919-85-8 |
| Formula | C32H35F6N7O3 |
| Molar Mass | 679.66 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Xu Y, et al., Crystal form of pyrimidine heterocyclic compound and preparation method therefor. WO2023036282. |
D3S-001
CAS: 2914919-85-8 F: C32H35F6N7O3 W: 679.66
D3S-001 is an orally active inhibitor for KRAS. D3S-001 inhibits the proliferation of KRASG12C mutant H358 and MIA-PA-CA
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.